SEP 20, 2019 5:36 PM PDT

Remarkable Results From First Gene Therapy for Glycogen Storage Disease

WRITTEN BY: Carmen Leitch

Dr. David Weinstein of the University of Connecticut School of Medicine and Connecticut Children's has presented the results from a one-year clinical trial testing a new gene therapy as a treatment for glycogen storage disease (GSD). Reporting at the Association for Glycogen Storage Disease's 41st Annual Conference, the results were called “remarkable.”

A subset of GSD, the rare genetic disorder GSD type Ia is caused by a mutation in a gene encoding for an enzyme, glucose-6-phosphatase-α, which controls the release of sugar from the liver. Blood sugar drops to dangerously low levels in affected individuals, and they constantly require cornstarch to feed their body’s need for glucose. It affects them all their lives, and missing a dose may cause a seizure or death.

The gene therapy was administered to three patients in 2018. In it, an injection to the bloodstream delivers a normal copy of the defective gene to the liver using a virus. The dysfunctional enzyme is replaced and the body can control glucose levels again.

A year after receiving an infusion of GSD vaccine, patient Jerrod Watts has been able to stop consuming cornstarch every day. His blood glucose is regulated normally, he has more strength and energy and has lost weight. Before the trial, he was ingesting over 400 grams (nearly one pound) of cornstarch on a daily basis.

"The clinical trial is going better than expected. The therapy is transforming patient lives," said Weinstein. "We have seen all of the patients wean their therapy with some already discontinuing treatment. Missed cornstarch doses no longer are resulting in hypoglycemia, which previously could have been life-threatening."

The researchers were surprised by the results of the study. "We were just making sure it was safe for humans to take, that was our initial goal. The results are way beyond my imagination," said Weinstein. "The patients who are finishing the first year got what we all thought was a test dose -- one-third strength -- yet the response has been dramatic. They can now go through the night without any treatment and they wake up clinically well."

Jerrod Watts, a patient enrolled in the first clinical trial for Glycogen Storage Disease, chats with lead investigator Dr. David Weinsten. Photos taken in the dedicated Glycogen Storage Disease Unit at UConn Health. / Credit:Tina Encarnacion/UConn Health

"The main thing I want to do is inspire hope. One of the biggest reliefs from this gene therapy is I can now sleep through the night without worrying about dying in the middle of the night. I wake up six to seven hours later with normal blood sugar," Watts said. "I'm living, breathing proof that there is a light at the end of the tunnel with GSD. I'm a completely different person now that I was a year ago. I feel like I can live a normal life and I can do anything I want to do now."

He had a message for other patients: "Please don't give up hope."

The other two trial participants are also seeing good results. They have been able to reduce their cornstarch intake.

"What's exciting is if it works this well with the low dose, what does the future hold?" said Weinstein. "If the patients are already coming off cornstarch and the labs are getting better, we just hope it will be even faster and more dramatic with the higher dose."

"This gene therapy treatment is something we've worked on for 21 years. This means so much to the glycogen storage disease community," noted Weinstein. "To see patients off cornstarch and doing so well really is a culmination of an incredible journey ... We feel like we're living history."

Sources: AAAS/Eurekalert! via University of Connecticut

About the Author
BS
Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
JUN 30, 2022
Cardiology
Greenlanders Face Genetic Heart Risks
JUN 30, 2022
Greenlanders Face Genetic Heart Risks
About one third of Greenlanders are at higher risk of heart disease and high cholesterol.
JUN 27, 2022
Genetics & Genomics
New detection method can locate DNA markers in advanced breast cancer within five hours
JUN 27, 2022
New detection method can locate DNA markers in advanced breast cancer within five hours
Breast cancer is the second most common cancer among women in the United States. For some alarming statistics, about 1 i ...
JUL 07, 2022
Neuroscience
Observing Gene Expression in Real-Time in Live Mouse Brains
JUL 07, 2022
Observing Gene Expression in Real-Time in Live Mouse Brains
Scientists still have a lot to learn about how memories are created and stored in the brain. The expression of genes lea ...
JUL 21, 2022
Clinical & Molecular DX
Scientists Find a Potential Cause and Treatment for Shorter Life Span in Men
JUL 21, 2022
Scientists Find a Potential Cause and Treatment for Shorter Life Span in Men
Scientists are beginning to understand the significant impact of a process called hematopoietic mosaic loss of Y chromos ...
AUG 04, 2022
Cell & Molecular Biology
Massive Gene Transfer From Bacteria to Fly is Discovered
AUG 04, 2022
Massive Gene Transfer From Bacteria to Fly is Discovered
Researchers used new long-read genetic sequencing technology to show that there are bacterial genomes within the genome ...
AUG 26, 2022
Genetics & Genomics
Many Stem Cell Lines Carry Serious Genetic Damage
AUG 26, 2022
Many Stem Cell Lines Carry Serious Genetic Damage
Stem cells hold tremendous potential, because they can specialize into any type of cell. During development, stem cells ...
Loading Comments...